Education
About Us
Working with TipRanks
Follow Us
Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
AARD Stock Chart & Stats
$13.92
--
Market closed
$13.92
--
Day’s Range― - ―
52-Week Range$4.88 - $19.58
Previous CloseN/A
VolumeN/A
Average Volume (3M)166.37K
Market Cap
$303.08M
Enterprise Value$163.19M
Total Cash (Recent Filing)$126.35M
Total Debt (Recent Filing)$545.00K
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Apr 06, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding21,773,272
10 Day Avg. Volume148,283
30 Day Avg. Volume166,372
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-3.38
Price to Sales (P/S)0.00
P/FCF Ratio-10.15
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.32K
Enterprise Value/Ebitda-3.14
Forecast
1Y Price Target
$33.38Price Target Upside139.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial Strength And ValuationThe cash position of $141.8M ensures financial stability for Aardvark, providing a runway into 2027.
Regulatory And Market PositionManagement confirmed 100% of participants who completed the HERO trial are enrolled in the OLE, suggesting strong retention and engagement.
Trial Enrollment And ProgressThe pivotal HERO trial for ARD-101 in Prader-Willi syndrome has begun enrolling patients in Australia, following strong enrollment in the U.S., indicating progress in advancing the program internationally.
Bears Say
Clinical Data And MechanismBoth the clinical data and the mechanism/biology behind ARD-101 are considered imperfect and present real risk.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $4.88 and its highest was $19.58 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $303.08M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
Aardvark Therapeutics, Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 109 days.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Aardvark Therapeutics, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.799 by $0.049.
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Undervalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate is -0.85.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,773,272 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Aardvark Therapeutics, Inc. reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.799. Following the earnings report the stock price went down -8.656%.
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aardvark Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.38 (139.80% Upside)
$33.38 (139.80% Upside)
Insider Transactions
Bought Shares
Worth $144.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.5%
Last 30 Days ▲ 13.2%
Last 30 Days ▲ 13.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-48.06%
Trailing 12-Months
Asset Growth
59.10%
Trailing 12-Months
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. (AARD) is a biotechnology company focused on developing innovative therapies for metabolic and inflammatory diseases. The company specializes in creating and advancing novel treatments aimed at addressing unmet medical needs in these sectors. Its core products include proprietary drug candidates designed to modulate metabolic pathways and reduce inflammation, ultimately improving patient outcomes and quality of life.
AARD Stock 12 Month Forecast
Average Price Target
$33.38
▲(139.80% Upside)
Technical Analysis
Annexon Biosciences
―
Nanobiotix
―
Alpha Tau Medical Ltd
―
OmniAb
―
Third Harmonic Bio, Inc.
―
Ownership Overview
42.42% Insiders
3.05% Mutual Funds
26.38% Other Institutional Investors
24.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---